Wordt geladen...
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Unlike conventional cancer treatment, immuno-oncology therapies are commonly associated with delayed clinical benefit and durable responses, as seen with immuno-oncology therapies for multiple myeloma (MM). Therefore, a longer-term approach to immuno-oncology data assessment is required. Appropriate...
Bewaard in:
| Gepubliceerd in: | Future Oncol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Future Medicine Ltd
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5705823/ https://ncbi.nlm.nih.gov/pubmed/28395525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2016-0504 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|